The distribution of cells from individual drug treatments visualised within the entire dataset.

The distribution of cells from individual drug treatments visualised within the entire dataset.</p

Assignment of drugs to phenotypic clusters based upon principle component analysis and k-means clustering.

The cluster assignment of cells treated with each drug from Fig 4 was analysed by principle component analysis (PCA). Clusters were assigned by k-means clustering and 5 clusters (A-E) was found to be optimal using the Elbow method. Images indicate exemplar cellular phenotypes for each drug treatment. Scale bar = 3μm.</p

Phenotypic distribution of male gametocytes treated with 45 transmission-blocking compounds.

2446 cells (augmented in eight different orientations) from 45 different treatments/controls were analysed by PhIDDLI and visualised by t-SNE and k-means clustering into nine clusters. (A) Localisation of the unactivated control samples (blue shades) and untreated control samples (red shades) within the dataset. Different shades indicate control cells from the six independent experiments comprising the entire screen. (B) The analysed dataset coloured by computed cluster identity. Images show representative cells from each cluster. The colour of the border surrounding the cell matches the cluster it represents. Scale bars = 3μm.</p

Using phenotypic imaging to cluster drug-treated cells with similar phenotypes.

(A) Raw fluorescence microscopy images were processed in ICY Bioimage Analysis to identify cells and then passed to the PhIDDLI pipeline for machine learning based clustering. (B) PhIDDLI interactive clustering output showing the distribution of cell phenotypes and navigable to view individual cells within each cluster.</p

Compounds targeting early male gametogenesis rapidly lose activity if administered later and compounds preventing induction of gametogenesis with a similar core structure show polypharmacology.

Cells were treated at 0, 2, 3, 5 or 10 min post-induction of gametogenesis and their resultant phenotypes studied at 20 min post-induction when a DMSO-treated control showed maximal levels of exflagellation. (A-C) TC02, TC05 and TC23 all showed early activity in the initial screen and so were compared together in the timecourse assay. (D-F) TC04, TC13 and TC41 which completely prevented induction of gametogenesis in the initial screen were evaluated with a known PKG inihibitor, ML-10. (A + D) PhIDDLI plots of clusters of identified cellular phenotypes that were manually assigned after visual inspection. (B + E) Representative cells from each identified cluster. (C + F) Quantification of how cells from each compound treatment change phenotypic cluster depending on timing of compound treatment. Scale bar = 4μm.</p

The activity of TCAMS compound identified in the Pf DGFA screen.

(A) 85 molecules were confirmed active in the Pf DGFA. 58 were previously identified in one or more transmission-blocking screens. (B) The majority of molecules displayed similar activity against male and female gametocytes, or biased/specific activity against male gametocytes. No molecule was identified with >4.7-fold greater activity against female gametocytes. Abbreviations (IC50 = concentration giving 50% inhibition, PbODA = P. berghei Ookinete Development Assay [5], PfDGFA = P. falciparum Dual Gamete Formation Assay, PfFGAA = P. falciparum Female Gametocyte Activation Assay [7], PfGCT = P. falciparum Gametocyte Viability ATP Assay [18]).</p

The PfDGFA potency of active compounds were determined and compared to cytotoxic activity against HepG2 cells (Activity: D = dual; M = male-biased; F = female-biased)

The PfDGFA potency of active compounds were determined and compared to cytotoxic activity against HepG2 cells (Activity: D = dual; M = male-biased; F = female-biased)</p

Comparing how male gametogenesis changes phenotypically when cells are treated with compounds at different times post-induction.

(A-C) Cells were treated at 0, 2, 5 or 10 min post-induction of gametogenesis with early-acting TC11, TC14 and TC16. Resultant phenotypes were then assessed at 20 min post-induction when a parallel DMSO treated control showed maximal levels of exflagellation. (D-F) The phenotype of late-acting TC39 and microtubule depolymeriser vinblastine were evaluated if cells were similarly treated 0, 2, 3, 5 or 10 min post-induction of gametogenesis. (A + D) PhIDDLI plots of clusters of identified cellular phenotypes that were manually assigned after visual inspection. (B + E) Representative cells from each identified cluster. (C + F) Quantification of how cells from each compound treatment change phenotypic cluster depending on timing of compound treatment. Scale bar = 4μm.</p

A model summarising the observed activity of studied compounds in the timecourse assays.

Normal male gametogenesis involves the cell rounding up, replicating its genome three times, assembling up to eight microtubule-rich flagellae, and emergence of male gametes. Integrating data from this study, transmission-blocking molecules were either observed to halt male gametogenesis or generate cells with an entirely different phenotype.</p

Principle component analysis (PCA) plot of the first two principle components (representing 56.8% of the total variance) of the cluster assignments from Fig 4.

The percentage of cells from each drug treatment falling into each of the 9 identified clusters was compared by PCA. All nine computed principle components were then used to cluster each drug phenotype by k-means clustering and the elbow method which determined 5 clusters was optimal. Cluster assignment is summarised in Fig 5. Bar = 3μm. (PDF)</p